Moderna, Inc. (MRNA) shares surged 7.13% in Monday's pre-market trading session, outpacing its earlier 5.9% gain, as investors appear to be refocusing on the company's long-term potential beyond its COVID-19 vaccine. The biotechnology firm has been making strides in expanding its mRNA pipeline and strengthening its global manufacturing capabilities.

A key driver of the stock's momentum could be Moderna's recent announcement of the first fully Canada-manufactured COVID-19 vaccine doses. This milestone not only marks a significant achievement for the company's supply chain but also underscores its commitment to global public health partnerships. The development may help support near-term sentiment as Moderna works to offset declining global COVID-19 vaccine sales and gain broader acceptance for its next-generation mRNA therapeutics.

Despite facing challenges, including its recent removal from the FTSE All-World Index and ongoing scrutiny of vaccine safety, investors seem to be betting on Moderna's future prospects. The company's outlook anticipates $3.5 billion in revenue and $498.6 million in earnings by 2028, assuming a 4.6% annual growth rate. This long-term view, coupled with the potential of Moderna's expanding pipeline beyond COVID-19, appears to be driving renewed interest in the stock, leading to today's significant price increase.